衍生结果的间接建模:微小的预测差异是否值得关注?

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY CPT: Pharmacometrics & Systems Pharmacology Pub Date : 2024-08-14 DOI:10.1002/psp4.13219
John P. Prybylski
{"title":"衍生结果的间接建模:微小的预测差异是否值得关注?","authors":"John P. Prybylski","doi":"10.1002/psp4.13219","DOIUrl":null,"url":null,"abstract":"<p>It is often a goal of model development to predict data from which a variety of outcomes can be derived, such as threshold-based categorization or change from baseline (CFB) transformations. This approach can improve power or support multiple decisions. Because these derivations are indirectly predicted from the model, they are valuable tests for misspecification when used in visual or numeric predictive checks (V/NPCs). However, derived outcome V/NPCs (especially if primary or key secondary) are often overly scrutinized and held to an uncommon standard when comparing model predictions to point estimates, even if by conventional standards both the directly and indirectly modeled data are captured well. Here, simulations of directly modeled data were used to determine where apparent issues in V/NPCs of derived outcomes are expected. Two types of datasets were simulated: (1) a simple pre–post study and (2) pharmacokinetic/pharmacodynamic data from a dose-ranging study. A psoriasis exposure–response model case study was also assessed. V/NPCs were generated on the raw data, CFB data, and placebo-corrected CFB (dCFB) data, and binned summary statistics of the observed data for each trial were graded as being strongly or weakly supportive of a predictive model (within the interquartile range or the 95% central distribution of all simulated trials, respectively). In all cases, the strength of support in direct data V/NPCs was minimally related to that in derived outcome V/NPCs. There are myriad benefits to modeling the underlying data of a derived measure, and these results support caution in discarding adequate models based on overly strict derived measure predictive checks.</p>","PeriodicalId":10774,"journal":{"name":"CPT: Pharmacometrics & Systems Pharmacology","volume":"13 10","pages":"1762-1770"},"PeriodicalIF":3.1000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494822/pdf/","citationCount":"0","resultStr":"{\"title\":\"Indirect modeling of derived outcomes: Are minor prediction discrepancies a cause for concern?\",\"authors\":\"John P. Prybylski\",\"doi\":\"10.1002/psp4.13219\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>It is often a goal of model development to predict data from which a variety of outcomes can be derived, such as threshold-based categorization or change from baseline (CFB) transformations. This approach can improve power or support multiple decisions. Because these derivations are indirectly predicted from the model, they are valuable tests for misspecification when used in visual or numeric predictive checks (V/NPCs). However, derived outcome V/NPCs (especially if primary or key secondary) are often overly scrutinized and held to an uncommon standard when comparing model predictions to point estimates, even if by conventional standards both the directly and indirectly modeled data are captured well. Here, simulations of directly modeled data were used to determine where apparent issues in V/NPCs of derived outcomes are expected. Two types of datasets were simulated: (1) a simple pre–post study and (2) pharmacokinetic/pharmacodynamic data from a dose-ranging study. A psoriasis exposure–response model case study was also assessed. V/NPCs were generated on the raw data, CFB data, and placebo-corrected CFB (dCFB) data, and binned summary statistics of the observed data for each trial were graded as being strongly or weakly supportive of a predictive model (within the interquartile range or the 95% central distribution of all simulated trials, respectively). In all cases, the strength of support in direct data V/NPCs was minimally related to that in derived outcome V/NPCs. There are myriad benefits to modeling the underlying data of a derived measure, and these results support caution in discarding adequate models based on overly strict derived measure predictive checks.</p>\",\"PeriodicalId\":10774,\"journal\":{\"name\":\"CPT: Pharmacometrics & Systems Pharmacology\",\"volume\":\"13 10\",\"pages\":\"1762-1770\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494822/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CPT: Pharmacometrics & Systems Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/psp4.13219\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CPT: Pharmacometrics & Systems Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/psp4.13219","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

模型开发的目标通常是预测数据,并从中得出各种结果,如基于阈值的分类或基线变化(CFB)转换。这种方法可以提高功率或支持多种决策。由于这些推导结果是从模型中间接预测出来的,因此在用于视觉或数字预测检查(V/NPCs)时,它们是检验规范错误的重要依据。然而,在将模型预测与点估计进行比较时,衍生结果 V/NPC(尤其是主要或关键次要结果)往往会受到过度审查,并被要求达到一个不常见的标准,即使按照常规标准,直接建模和间接建模的数据都能很好地捕捉到。在此,我们使用直接建模数据进行模拟,以确定衍生结果的 V/NPCs 中预计会出现明显问题的地方。模拟了两类数据集:(1) 简单的前后研究;(2) 来自剂量范围研究的药代动力学/药效学数据。还对牛皮癣暴露-反应模型案例研究进行了评估。对原始数据、CFB 数据和安慰剂校正 CFB(dCFB)数据生成 V/NPC,并将每个试验的观察数据的分选汇总统计量分为对预测模型的强支持或弱支持(分别在所有模拟试验的四分位数间范围或 95% 中心分布范围内)。在所有情况下,直接数据 V/NPC 的支持强度与衍生结果 V/NPC 的支持强度关系不大。对衍生指标的基础数据建模有很多好处,这些结果支持在基于过于严格的衍生指标预测检查而放弃适当模型时要谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Indirect modeling of derived outcomes: Are minor prediction discrepancies a cause for concern?

It is often a goal of model development to predict data from which a variety of outcomes can be derived, such as threshold-based categorization or change from baseline (CFB) transformations. This approach can improve power or support multiple decisions. Because these derivations are indirectly predicted from the model, they are valuable tests for misspecification when used in visual or numeric predictive checks (V/NPCs). However, derived outcome V/NPCs (especially if primary or key secondary) are often overly scrutinized and held to an uncommon standard when comparing model predictions to point estimates, even if by conventional standards both the directly and indirectly modeled data are captured well. Here, simulations of directly modeled data were used to determine where apparent issues in V/NPCs of derived outcomes are expected. Two types of datasets were simulated: (1) a simple pre–post study and (2) pharmacokinetic/pharmacodynamic data from a dose-ranging study. A psoriasis exposure–response model case study was also assessed. V/NPCs were generated on the raw data, CFB data, and placebo-corrected CFB (dCFB) data, and binned summary statistics of the observed data for each trial were graded as being strongly or weakly supportive of a predictive model (within the interquartile range or the 95% central distribution of all simulated trials, respectively). In all cases, the strength of support in direct data V/NPCs was minimally related to that in derived outcome V/NPCs. There are myriad benefits to modeling the underlying data of a derived measure, and these results support caution in discarding adequate models based on overly strict derived measure predictive checks.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.00
自引率
11.40%
发文量
146
审稿时长
8 weeks
期刊最新文献
Clinical study design strategies to mitigate confounding effects of time-dependent clearance on dose optimization of therapeutic antibodies. Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products. Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension. Issue Information Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1